Trial Profile
To assess the efficacy and safety of the combination of Genexol-PM (a Novel Cremophor-Free) and carboplatin for the treatment of advanced non-small-cell lung cancer (NSCLC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer